体外式および埋込型心臓除細動器の世界市場：2025年～2033年

体外式および埋込型心臓除細動器の世界市場は、2024年に65億8,000万米ドルに達し、2033年には121億6,000万米ドルに達すると予測され、予測期間2025年にはCAGR 7.1％で成長すると予測されています。

除細動器の技術的進歩の高まりは、体外式および埋込型心臓除細動器市場の成長を大きく後押ししており、予測期間中も市場を牽引すると予想されます。Zoll MedicalのLifeVestやElement ScienceのJewel Wearable Patch Cardioverter Defibrillatorなどのウェアラブル除細動器は、突然の心停止（SCA）のリスクが高いがICDの候補にはなっていない患者に非侵襲的なソリューションを提供します。これらのウェアラブルデバイスは、心臓のリズムをモニターし、必要なときに自動的にショックを与えます。

例えば、2024年7月、Element Scienceは、Jewel Wearable Patch Cardioverter Defibrillator（Jewel）が名誉あるレッドドット・デザイン賞を受賞したと発表しました。この賞は、Jewelのユニークなデザインが国際的に評価されたことを示すもので、患者の快適性に重点を置きながら、心臓発作などの心事故発生後の数週間から数ヵ月間に一般的に発生する突然心臓停止（SCA）リスクの一時的な上昇から継続的に保護するものです。

埋込型除細動器（ICD）と自動体外式除細動器（AED）のバッテリー技術の向上により、これらの機器の寿命が大幅に延び、頻繁な交換の必要性が減少しました。ICDの場合、バッテリー寿命は7～10年に延長され、機器の長期使用可能性が向上し、ヘルスケアコストが削減されています。

例えば、MedtronicのEvera MRI ICDのようにバッテリー寿命が延長された機器（最長10年）は、患者やヘルスケアプロバイダーの総所有コストを削減し、市場成長に貢献しています。また、機器をより長期間使用できるため、患者ケアの向上にもつながります。

当レポートでは、世界の体外式および埋込型心臓除細動器市場について調査し、市場の概要とともに、製品タイプ別、患者タイプ別、エンドユーザー別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 エグゼクティブの洞察と重要なポイント

第3章 市場力学

• 影響要因
  • 促進要因
  • 抑制要因
  • 機会
  • 影響分析

第4章 戦略的洞察と業界の展望

• 市場のリーダーと先駆者
• CXOの視点
• 最新の開発とブレークスルー
• ケーススタディ/進行中の調査
• 規制と償還の情勢
• ポーターのファイブフォース分析
• サプライチェーン分析
• 特許分析
• SWOT分析
• アンメットニーズとギャップ
• 市場参入と拡大のための推奨戦略
• シナリオ分析ベストケース、ベースケース、ワーストケースの予測
• 価格分析と価格動向
• キーオピニオンリーダー

第5章 体外式および埋込型心臓除細動器市場、製品タイプ別

• 埋込型除細動器（ICD）
• 体外式除細動器

第6章 体外式および埋込型心臓除細動器市場、患者タイプ別

• 大人
• 小児

第7章 体外式および埋込型心臓除細動器市場、エンドユーザー別

• 病院
• 専門クリニック
• 在宅ヘルスケア
• その他

第8章 体外式および埋込型心臓除細動器市場、地域別市場分析と成長機会

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他
• 中東・アフリカ

第9章 競合情勢と市場ポジショニング

第10章 企業プロファイル

• Koninklijke Philips NV
• Nihon Kohden Corporation
• Medtronic plc
• Boston Scientific Corporation
• Stryker Corporation
• ZOLL Medical Corporation
• Abbott Laboratories
• MicroPort Medical Products Ltd.
• LivaNova PLC
• Mindray Medical India Pvt. Ltd.

第11章 仮定と調査手法

第12章 付録

The global external and implantable cardiac defibrillators market reached US$ 6.58 billion in 2024 and is expected to reach US$ 12.16 billion by 2033, growing at a CAGR of 7.1% during the forecast period 2025-2033.

External and implantable cardiac defibrillators are medical devices designed to treat life-threatening cardiac arrhythmias, such as ventricular fibrillation (VF) and ventricular tachycardia (VT), by delivering a controlled electric shock to restore normal heart rhythm. Implantable cardiac defibrillators (ICDs) are surgically implanted inside the body and are used for continuous monitoring and treatment of abnormal heart rhythms. They are typically prescribed to patients at high risk of sudden cardiac arrest (SCA) due to conditions like congenital heart defects, cardiomyopathy, heart failure, or a history of life-threatening arrhythmias.

External defibrillators are portable, non-invasive devices used in emergency situations to deliver an electric shock to the heart through electrode pads placed on the chest. These devices are commonly used by first responders, emergency medical teams, and public access locations (like airports, malls, and sports arenas) to restore normal heart rhythm during sudden cardiac arrest. Automated external defibrillators (AEDs) are the most commonly used external defibrillators. They are designed to be user-friendly, with built-in algorithms to analyze the heart's rhythm and automatically deliver shocks if necessary. AEDs can be used by bystanders with minimal training.

The market demand for external and implantable cardiac defibrillators is driven by a combination of medical needs, technological advancements and rising awareness about cardiovascular health. The global increase in cardiovascular diseases (CVDs) including heart attacks, arrhythmias, heart failure and sudden cardiac arrest has created a growing need for both external and implantable defibrillators. For instance, according to the National Institute of Health, cardiovascular diseases (CVDs) are the leading cause of deaths globally. Of the 20.5 million CVD-related deaths in 2021, approximately 80% occurred in low- and middle-income countries.

Market Dynamics: Drivers & Restraints

Technological Advancements in Defibrillator Devices

The rising technological advancements in defibrillator devices are significantly driving the growth of the external and implantable cardiac defibrillators market and are expected to drive the market over the forecast period. Wearable cardioverter defibrillators, such as the LifeVest by Zoll Medical and Jewel Wearable Patch Cardioverter Defibrillator by Element Science, offer a non-invasive solution for patients who are at high risk for sudden cardiac arrest (SCA) but are not yet candidates for an ICD. These wearable devices monitor heart rhythms and automatically deliver shocks when necessary.

For instance, in July 2024, Element Science announced that its Jewel Wearable Patch Cardioverter Defibrillator (Jewel) received the prestigious Red Dot Design Award. This award signals international recognition of Jewel's unique design, focusing on patient comfort while delivering continuous protection from temporary periods of elevated Sudden Cardiac Arrest (SCA) risk, which typically occurs in the weeks to months after suffering a cardiac event, such as a heart attack.

Improved battery technology in both implantable cardioverter defibrillators (ICDs) and automated external defibrillators (AEDs) has significantly extended the life of these devices, reducing the need for frequent replacements. In the case of ICDs, the battery life has been extended to 7-10 years, which improves the long-term viability of the device and reduces healthcare costs.

For instance, the extended battery life in devices like the Medtronic Evera MRI ICD (which lasts for up to 10 years) has contributed to market growth by reducing the overall cost of ownership for patients and healthcare providers. It also ensures that devices are available for longer periods, thus improving patient care.

Complications and Safety Concerns

Despite their critical role in saving lives, complications and safety concerns related to both external and implantable cardiac defibrillators have been significant challenges, slowing the growth of the market. These issues impact patient outcomes, clinical adoption and cost-effectiveness, contributing to hesitation in both prescribing and using these devices.

One of the most significant concerns with implantable cardioverter defibrillators (ICDs) is the possibility of unnecessary shocks, which can cause physical and psychological harm to patients. False or inappropriate shocks can lead to patient anxiety, depression and a diminished quality of life. For instance, according to a study in the Journal of the American College of Cardiology, inappropriate shocks occur in about 13% of ICD patients, and these shocks can lead to increased hospitalizations, psychological distress, and potential harm to the patient.

In implantable defibrillators, malfunctions related to the device's leads (wires) or battery can result in device failure, necessitating surgery for replacement or repair. Complications like lead displacement, infection, or hardware failure may require costly interventions. For instance, according to an announcement from the US Food and Drug Administration, Medtronic is recalling nearly 350,000 implantable cardiac devices due to continued problems with the delivery of high-voltage energy. The recall is categorized as a Class I, the most serious type.

Segment Analysis

The global external and implantable cardiac defibrillators market is segmented based on product type, imaging modality, application, procedure type, end-user and region.

Product Type:

The external defibrillators segment is expected to dominate the external and implantable cardiac defibrillators market share

The increasing adoption of automated external defibrillators (AEDs) in public spaces like airports, shopping malls, schools, stadiums, homes and train stations has played a pivotal role in driving the demand for external defibrillators. Public access to AEDs is essential in emergencies, providing life-saving interventions before emergency medical teams arrive. For instance, according to the National Institute of Health (NIH), sudden cardiac death from ventricular arrhythmia kills about 350,000 people annually in the United States. About 70% of sudden cardiac deaths occur at home, where an AED is usually unavailable. This further accelerates the demand for AEDs.

The introduction of next-generation AEDs has revolutionized the way defibrillators are used in emergencies. Newer models come with features like real-time data transmission, cloud connectivity, AI-powered algorithms, and improved battery life. The next-generation AEDs are more efficient and reliable, which is a key factor contributing to their dominance in the market.

For instance, in March 2024, Stryker launched a next-generation LIFEPAK CR2 automated external defibrillator (AED) for cardiac care. The LIFEPAK CR2 is a revolutionary defibrillator designed to empower rescuers to provide high-quality CPR and deliver instant shock during sudden cardiac arrest (SCA) emergencies. This innovative device incorporates QUIK-STEP electrodes which peel directly off the base for faster placement on the patient's chest and a Shock Advisory System which is an ECG analysis system that advises whether a shock is appropriate.

Geographical Analysis

North America is expected to hold a significant position in the external and implantable cardiac defibrillators market share

Cardiovascular diseases, including sudden cardiac arrest, arrhythmias and heart failure, are among the leading causes of death in North America particularly in the United States, contributing to the growing need for life-saving cardiac devices such as defibrillators. For instance, according to the Cardiac Arrest Foundation, there are more than 356,000 out-of-hospital cardiac arrests annually in the United States.

North America has extensive public education and CPR/AED training programs, increasing the number of trained individuals who are capable of using AEDs in emergency situations. This has contributed to a higher survival rate and widespread acceptance of defibrillators in both healthcare settings and public spaces.

For instance, in all, over 20 million people worldwide every year learn CPR through the American Heart Association (AHA). In the U.S., around 90% of healthcare providers have received AHA training. which has positively influenced the market by increasing the number of laypersons who can assist in life-saving procedures.

Additionally, in September 2024, the Smart Heart Sports Coalition launched the "AEDs for Youth" program, offering automated external defibrillators (AEDs) to schools and youth sports organizations at substantial discounts. In collaboration with leading AED companies Avive Solutions and Coro Medical, the program makes AEDs more accessible as students, teachers and athletes begin the new school year.

Asia-Pacific is growing at the fastest pace in the external and implantable cardiac defibrillators market

The Asia Pacific region has seen a significant increase in the prevalence of cardiovascular diseases (CVDs), which is a major driver for the demand for defibrillators. Changing lifestyles, rising levels of obesity, poor diet habits, increased smoking and sedentary behavior have contributed to the growing burden of heart diseases.

For instance, according to the World Health Organization (WHO), nearly 80% of CVD deaths occur in low- and middle-income countries in the APAC region. As per the Indian Heart Association, the annual number of deaths from CVD in India has risen from 2.26 million (1990) to 4.77 million (2020), leading to an urgent need for devices like ICDs and AEDs.

Many countries in the APAC region, particularly China, India, Japan and South Korea, have been rapidly improving their healthcare infrastructure. Governments and other private institutions have been raising awareness about the importance of defibrillators, leading to greater accessibility to advanced medical devices like implantable defibrillators (ICDs) and external defibrillators (AEDs).

For instance, in February 2024, the Udgam Group of Schools in Gujarat installed an Automated External Defibrillator (AED) in the premises of Udgam School for Children, Zebar School for Children, Satellite School for Children & Bodakdev School for Children. The initiative is part of a broader campaign to promote the usage of this life-saving technology in public spaces, particularly schools and colleges, with Udgam Group of Schools leading the way. These programs, often promoted by health organizations, government agencies, and NGOs, have significantly boosted AED usage in public places and emergencies.

Competitive Landscape

The major global players in the external and implantable cardiac defibrillators market include Koninklijke Philips N.V., Nihon Kohden Corporation, Medtronic plc, Boston Scientific Corporation, Stryker Corporation, ZOLL Medical Corporation, Abbott Laboratories, MicroPort Medical Products Ltd., LivaNova PLC, Mindray Medical India Pvt. Ltd. and among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global external and implantable cardiac defibrillators market report delivers a detailed analysis with 62 key tables, more than 51 visually impactful figures, and 171 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Product Type
• 2.4. Snippet by Patient Type
• 2.5. Snippet by End-User
• 2.6. Snippet by Region

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Technological Advancements in Defibrillator Devices
  • 3.1.2. Restraints
    • 3.1.2.1. Complications and Safety Concerns
  • 3.1.3. Opportunity
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with largest selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. CXO Perspectives
• 4.3. Latest Developments and Breakthroughs
• 4.4. Case Studies/Ongoing Research
• 4.5. Regulatory and Reimbursement Landscape
  • 4.5.1. North America
  • 4.5.2. Europe
  • 4.5.3. Asia Pacific
  • 4.5.4. Latin America
  • 4.5.5. Middle East & Africa
• 4.6. Porter's Five Force Analysis
• 4.7. Supply Chain Analysis
• 4.8. Patent Analysis
• 4.9. SWOT Analysis
• 4.10. Unmet Needs and Gaps
• 4.11. Recommended Strategies for Market Entry and Expansion
• 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.13. Pricing Analysis and Price Dynamics
• 4.14. Key Opinion Leaders

5. External and Implantable Cardiac Defibrillators Market, By Product Type

• 5.1. Introduction
  • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 5.1.2. Market Attractiveness Index, By Product Type
• 5.2. Implantable Cardioverter Defibrillators (ICDs)*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.2.3. Transvenous ICDs (T-ICDs)
  • 5.2.4. Subcutaneous ICDs (S-ICDs)
  • 5.2.5. Cardiac Resynchronization Therapy Defibrillators (CRT-Ds)
• 5.3. External Defibrillators
  • 5.3.1. Automated External Defibrillators (AEDs)
  • 5.3.2. Manual and Semi-Automatic External Defibrillators
  • 5.3.3. Wearable Cardioverter Defibrillators

6. External and Implantable Cardiac Defibrillators Market, By Patient Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
  • 6.1.2. Market Attractiveness Index, By Patient Type
• 6.2. Adults*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Pediatrics

7. External and Implantable Cardiac Defibrillators Market, By End-User

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.1.2. Market Attractiveness Index, By End-User
• 7.2. Hospitals*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Specialty Clinics
• 7.4. Home Healthcare
• 7.5. Others

8. External and Implantable Cardiac Defibrillators Market, By Regional Market Analysis and Growth Opportunities

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.6.1. U.S.
    • 8.2.6.2. Canada
    • 8.2.6.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.6.1. Germany
    • 8.3.6.2. U.K.
    • 8.3.6.3. France
    • 8.3.6.4. Spain
    • 8.3.6.5. Italy
    • 8.3.6.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.6.1. Brazil
    • 8.4.6.2. Argentina
    • 8.4.6.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.6.1. China
    • 8.5.6.2. India
    • 8.5.6.3. Japan
    • 8.5.6.4. South Korea
    • 8.5.6.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
  • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

• 9.1. Competitive Overview and Key Market Players
• 9.2. Market Share Analysis and Positioning Matrix
• 9.3. Strategic Partnerships, Mergers & Acquisitions
• 9.4. Key Developments in Product Portfolios and Innovations
• 9.5. Company Benchmarking

10. Company Profiles

• 10.1. Koninklijke Philips N.V.*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio and Description
  • 10.1.3. Financial Overview
  • 10.1.4. Key Developments
  • 10.1.5. SWOT Analysis
• 10.2. Nihon Kohden Corporation
• 10.3. Medtronic plc
• 10.4. Boston Scientific Corporation
• 10.5. Stryker Corporation
• 10.6. ZOLL Medical Corporation
• 10.7. Abbott Laboratories
• 10.8. MicroPort Medical Products Ltd.
• 10.9. LivaNova PLC
• 10.10. Mindray Medical India Pvt. Ltd.

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

• 11.1. Data Collection Methods
• 11.2. Data Triangulation
• 11.3. Forecasting Techniques
• 11.4. Data Verification and Validation

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us